Coda’s chemogenetic control

Coda to bring chemogenetically activated gene therapy to the clinic with $19M

Coda Biotherapeutics Inc. could have first-mover potential in the chemogenetics space, and with a newly raised $19 million series A round, the company will move its first program toward the clinic.

Seed investors MPM Capital and Versant Ventures led the round, which

Read the full 422 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE